BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Pfizer

Moderna Inc. MRNA, +0.44% said Friday it is suing Pfizer Inc. PFE, +0.99% and German partner BioNTech SE BNTX, +1.59% for infringing patents relating to its mRNA platform, the source of the COVID vaccines developed by the three parties. The suit is to be filed Friday in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.

Moderna sues Pfizer and BioNTech for patent infringement relating to the mRNA platform used to develop COVID vaccines

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine

Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.

Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization

The three-dose vaccine was most effective in children ages 6 months to 2 years, with a 75.8% efficacy rate, according to the study.

Pfizer-BioNTech Covid Vaccine Is 73% Effective In Young Children, Study Finds

Pfizer and German partner BioNTech on Tuesday offered updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age.

Pfizer and BioNTech say data shows COVID vaccine has more than 70% efficacy in small children, and cases now rising in just 7 states

Pfizer Inc. PFE, -0.51% and German partner BioNTech SE BNTX, +0.26% on Tuesday announced updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age. The companies said updated analysis from 34 cases occurring at least seven days after a three-dose regimen showed 73.2% vaccine efficacy among children in that age group.

Pfizer and BioNTech say COVID vaccine data showed 73.2% efficacy among children aged 6 month to 4 years

NEW YORK and MAINZ, GERMANY, AUGUST 23, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data collected in March and April 2022. Emergency Use Authorization (EUA) of this vaccine was granted by the U.S. Food and Drug Administration (FDA) for this age group on June 17 and an application for conditional marketing authorization in this age group is under review by the European Medicines Agency (EMA).

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age

Pfizer PFE, -0.51% and BioNTech BNTX, +0.26% have formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains, the latter of which is now the dominant strain of SARS-CoV-2 in the U.S. The news comes as U.S. known cases of COVID are continuing to ease, although the true tally is likely higher given how many people are testing at home, where the data are not being collected.

Coronavirus tally: Pfizer and BioNTech formally apply for FDA nod for bivalent COVID booster for people aged 12 and older

Pfizer Inc. PFE, -0.36% and BioNTech SE BNTX, +0.21% said Monday that they formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains.

Pfizer, BioNTech complete FDA submission for new COVID-19 booster

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. The application follows guidance from the FDA to include clinical data from the companies' bivalent Omicron BA.1-adapted vaccine and pre-cli

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

Pfizer's diversified portfolio of medicines will ensure it keeps outperforming BioNTech.

1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)

Its flagship vaccine product isn't selling as much as it used to.

Is This Battered Growth Stock Still a Buy After Its Latest Stumble?

Fresh analyst price target cuts dampen investor sentiment on the biotech stock.

Why BioNTech Was Tumbling Again Today

The company's top and bottom lines both declined considerably in the second quarter.

Why BioNTech Was a Sickly Stock on Monday

BioNTech SE (NASDAQ:BNTX ) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations and Strategy Ugur Sahin - Chief Executive Officer and Co-Founder Ozlem Tureci - Chief Medical Officer and Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Zhiqiang Shu - Berenberg Operator Welcome to the BioNTech Second Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas.

BioNTech SE (BNTX) CEO Ugur Sahin on Q2 2022 Results - Earnings Call Transcript

BioNTech (BNTX) misses estimates for both earnings and revenues in the second quarter of 2022.

BioNTech's (BNTX) Earnings & Revenues Miss Estimates in Q2

Source: Palatinate Stock / Shutterstock.com BioNTech (NASDAQ: BNTX ) stock is on falling on Monday after the company released poor results for its second quarter of 2022. This saw it report diluted earnings per share of 6.45 euros and revenue of 3.2 billion euros.

Why Is BioNTech (BNTX) Stock Down 7% Today?

BioNTech lagged second-quarter expectations and issued light 2022 guidance on Monday, leading BNTX stock to dive. The post BioNTech Dives As Second-Quarter Sales, Profit Broadly Miss Forecasts appeared first on Investor's Business Daily.

BioNTech Dives As Second-Quarter Sales, Profit Broadly Miss Forecasts

BioNTech and its U.S. partner Pfizer have already begun manufacturing Covid-19 boosters that are adapted for multiple Omicron sub variants including BA.1, BA.4 and BA.5.

Vaccine Targeting Fast-Spreading Omicron Subvariants Could Be Ready For Fall As Pfizer, BioNTech Announce Trials

The company, which partnered with Pfizer to develop the first Covid-19, vaccine approved for use in the U.S. says its Omicron-adapted vaccines should be ready for delivery as early as October.

BioNTech Misses Earnings Estimates

BioNTech expects to begin deliveries of two Omicron-adapted vaccines as soon as October, which will help spur demand in the fourth quarter, said the German biotech firm as it reaffirmed its vaccine revenue guidance for the year on Monday.

BioNTech expects Omicron-adapted vaccine deliveries as soon as October

The company reports second-quarter earnings of €6.45 a share on revenue of €3.2 billion.

BioNTech Earnings and Revenue Miss Expectations

The U.S.-listed shares of Germany-based BioNTech SE BNTX, +1.48% sank 8.2% in premarket trading Monday, after the biotechnology company and Pfizer Inc. PFE, -1.18% partner in developing a COVID-19 vaccine reported second-quarter profit and revenue that fell below expectations but affirmed its full-year COVID-19 revenue outlook. Net income dropped to EUR1.67 billion ($1.70 bln), or EUR6.45 a share, from EUR2.79 billion, or EUR10.77 a share, in the year-ago period.

BioNTech stock sinks more than 8% after profit, revenue fall below expectations

Conference call and webcast scheduled for August 8, 2022, at 8:00 am ET (2:00 pm CET)

BioNTech Announces Second Quarter Financial Results and Corporate Update

MAINZ, Germany, and COPENHAGEN, Denmark, August 5, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Genmab A/S (“Genmab”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. Under this expansion, BioNTech and Genmab will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development of bispecific cancer antibodies aimed at improving immunotherapy options for cancer patients.

News for BioNTech SE Stock (BNTX)